While trade names often attract the atten\u00adtion of marketers and pati\u00adents, the greater benefit for medical prac\u00adtice lies in the logic of Inter\u00adna\u00adtional Nonpro\u00adprie\u00adtary Names (INNs). These are not only unified iden\u00adti\u00adfiers, but also convey phar\u00adma\u00adco\u00adlo\u00adgical infor\u00adma\u00adtion \u2013 a kind of \u2018lingu\u00adi\u00adstic coding\u2019.
\nClas\u00adsi\u00adfi\u00adca\u00adtion by name stems
\nMany INN endings have a signal\u00adling func\u00adtion and make orien\u00adta\u00adtion easier:
\n\u2011olol = beta blockers (meto\u00adprolol, bisoprolol)
\n\u2011pril = ACE inhi\u00adbi\u00adtors (enalapril, lisinopril)
\n\u2011sartan = AT1 antago\u00adnists (vals\u00adartan, losartan)
\n\u2011mab = mono\u00adclonal anti\u00adbo\u00addies (adali\u00admumab, trastuzumab)
\n\u2011tinib = tyro\u00adsine kinase inhi\u00adbi\u00adtors (imat\u00adinib, osimertinib)
\nParti\u00adcu\u00adlarly in the case of onco\u00adlo\u00adgical agents, where new subs\u00adtances are approved every year, this syste\u00admatic struc\u00adture is an important tool for clas\u00adsi\u00adfying the mecha\u00adnism of action at least roughly. Of course, the full thera\u00adpeutic context must be further differentiated.
\nDiffe\u00adren\u00adtia\u00adtion and pitfalls
\nHowever, the nomen\u00adcla\u00adture is not always intui\u00adtive. Suffixes such as \u2011ximab (chimeric mAbs) or \u2011zumab (huma\u00adnised mAbs) repre\u00adsent subtle struc\u00adtural diffe\u00adrences that are clini\u00adcally rele\u00advant, for example in terms of immu\u00adno\u00adge\u00adni\u00adcity. The situa\u00adtion regar\u00adding \u2011tinibs is similar: not every tyro\u00adsine kinase inhi\u00adbitor attacks the same target, even if the name suggests that the subs\u00adtances are closely related.
\nIn addi\u00adtion, similar-sounding names carry risks: hydralazine versus hydro\u00adxy\u00adzine, cele\u00adcoxib versus Celexa\u00ae (citalo\u00adpram, USA). Inter\u00adna\u00adtional autho\u00adri\u00adties such as the EMA and FDA ther\u00ade\u00adfore strictly check for possible confu\u00adsion, but in clinical reality, \u2018look-alike, sound-alike drugs\u2019 remain an issue \u2013 with docu\u00admented medi\u00adca\u00adtion errors.
\nBene\u00adfits in ever\u00adyday medical practice
\nEspe\u00adci\u00adally in hospital settings, where trade names can vary depen\u00adding on the country or even the hospital form, orien\u00adta\u00adtion via INN endings is often the more reliable stra\u00adtegy. A ward doctor imme\u00addia\u00adtely reco\u00adg\u00adnises that a drug ending in \u2011pril or \u2011sartan belongs to anti\u00adhy\u00adper\u00adten\u00adsive therapy \u2013 even if he has never encoun\u00adtered the brand name before.
\nLingu\u00adi\u00adstic balance
\nA recur\u00adring topic in WHO expert commit\u00adtees is the tension between precision and prac\u00adti\u00adcality. Tongue twis\u00adters such as \u2018obinu\u00adtu\u00adzumab\u2019 are scien\u00adti\u00adfi\u00adcally correct, but not very user-friendly in ever\u00adyday life. This is where the balan\u00adcing act comes in: as much infor\u00adma\u00adtion as neces\u00adsary, as concise as possible.
\nWhen names make a big impres\u00adsion: Tall Man lettering
\nA some\u00adwhat uncon\u00adven\u00adtional but very effec\u00adtive trick in drug nomen\u00adcla\u00adture is Tall Man lette\u00adring. This involves deli\u00adbera\u00adtely capi\u00adta\u00adli\u00adsing certain letters in an active ingre\u00addient name \u2013 for example, pred\u00adni\u00adSONE and predn\u00adiSO\u00adLONE. The emphasis is intended to make similar-looking names more distin\u00adgu\u00adis\u00adhable and thus prevent medi\u00adca\u00adtion errors.
\nAnd why is it called \u2018Tall Man\u2019? Quite lite\u00adrally: the large letters \u2018stand out\u2019 like tall people in a crowd \u2013 they are not easily over\u00adlooked. This is intended to help doctors and phar\u00admacists reco\u00adg\u00adnise more quickly in ever\u00adyday life that these are two diffe\u00adrent substances.
\nConclusion
\nFor doctors, drug names are more than just labels \u2013 they are tools for orien\u00adta\u00adtion. Name stems enable quick clas\u00adsi\u00adfi\u00adca\u00adtion, endings often reveal the mecha\u00adnism of action, and diffe\u00adrences in syll\u00adables can have clinical rele\u00advance. Those who are fami\u00adliar with the system have an advan\u00adtage: in reco\u00adg\u00adnising new subs\u00adtances, avoi\u00adding confu\u00adsion and quickly trans\u00adfer\u00adring guide\u00adlines into prescrip\u00adtion prac\u00adtice. And if neces\u00adsary, CAPI\u00adTA\u00adLI\u00adSA\u00adTION helps\u2026<\/p>\n","protected":false},"excerpt":{"rendered":"
While trade names often attract the atten\u00adtion of marketers and pati\u00adents, the greater benefit for medical prac\u00adtice lies in the logic of Inter\u00adna\u00adtional Nonpro\u00adprie\u00adtary Names (INNs). These are not only unified iden\u00adti\u00adfiers, but also convey phar\u00adma\u00adco\u00adlo\u00adgical infor\u00adma\u00adtion \u2013 a kind of \u2018lingu\u00adi\u00adstic coding\u2019. Clas\u00adsi\u00adfi\u00adca\u00adtion by name stems Many INN endings have a signal\u00adling func\u00adtion and make [\u2026]<\/p>\n","protected":false},"author":4,"featured_media":1891,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-1893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en"],"yoast_head":"\n